We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00919113
Recruitment Status : Completed
First Posted : June 12, 2009
Results First Posted : May 3, 2013
Last Update Posted : May 3, 2013
Information provided by (Responsible Party):
Watson Pharmaceuticals

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Interstitial Cystitis
Painful Bladder Syndrome
Interventions: Drug: 2% sodium chondroitin sulfate
Drug: Placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Uracyst 2% sodium chondroitin sulfate
Placebo identical buffer

Participant Flow:   Overall Study
    Uracyst   Placebo
STARTED   50   48 
Received Uracyst   49 [1]   0 
Received Placebo   0   49 [1] 
COMPLETED   41   40 
[1] One subject was misrandomized. Actual treatment was used for Demographic and Safety analysis.

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Uracyst 2% sodium chondroitin sulfate
Placebo identical buffer
Total Total of all reporting groups

Baseline Measures
   Uracyst   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 49   49   98 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   45   45   90 
>=65 years   4   4   8 
[Units: Years]
Mean (Standard Deviation)
 44.4  (14.6)   46.8  (14.1)   45.6  (14.3) 
[Units: Participants]
Female   49   49   98 
Male   0   0   0 
Region of Enrollment 
[Units: Participants]
United States   49   49   98 

  Outcome Measures

1.  Primary:   Global Response Assessment (GRA) Responders at Week 11.   [ Time Frame: at week 11 ]

2.  Secondary:   Interstitial Cystitis Symptom Index (ICSI) Responders at Week 11.   [ Time Frame: at week 11 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Gary Hoel, RPh PhD, VP Global Brands Clinical Research
Organization: Watson Laboratories, Inc.
phone: 801 588-6641
e-mail: gary.hoel@watson.com

Responsible Party: Watson Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00919113     History of Changes
Other Study ID Numbers: UR08004
First Submitted: June 11, 2009
First Posted: June 12, 2009
Results First Submitted: February 5, 2013
Results First Posted: May 3, 2013
Last Update Posted: May 3, 2013